Agios Pharmaceuticals Inc banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
United States of America US
Employees
539
IPO date
Jul 24, 2013

Agios Pharmaceuticals is a biotech company that develops medicines for rare blood disorders. Its main approved drug is Pyrukynd, a pill used to treat certain inherited anemia conditions by helping red blood cells make energy more efficiently. The company also keeps working on other drug candidates in rare hematology, using the same idea of targeting cell metabolism.

Agios makes money mainly by selling its approved medicine to patients through doctors, specialty pharmacies, and health systems. It may also earn partnership payments, milestones, or royalties from collaboration deals tied to older drug programs. That mix means the business is built around turning a small number of specialized treatments into recurring drug sales, rather than selling a broad range of products.

What makes Agios different is its focus on a narrow group of diseases that are hard to treat and often need long-term therapy. Instead of competing in crowded primary-care markets, it works in rare disease areas where doctors and payers look for targeted medicines with clear clinical value.

Agios Pharmaceuticals Inc Investor Relations

Address
88 Sidney Street
Cambridge, Massachusetts
United States of America

Business Segments

Rare disease medicine sales

Agios sells prescription medicine for certain inherited blood disorders, including treatments used by patients with pyruvate kinase deficiency and related hemolytic anemias.

Customers and revenue model

Drug development

Agios researches and develops new medicines for rare blood diseases and other serious conditions, moving drug candidates through lab work and clinical testing.

Customers and revenue model

Management

Ms. Cecilia Jones

Chief Financial Officer

Biography unavailable

Ms. Tsveta Milanova

Chief Commercial Officer

Biography unavailable

Dr. Shin-San Su Ph.D.

Founder

Biography unavailable

Mr. T. J. Washburn

VP, Controller & Principal Accounting Officer

Biography unavailable

Dr. Clive Patience Ph.D.

Chief Technical Operations Officer

Biography unavailable

Mr. Christopher J. M. Taylor

Vice President of Investor Relations & Corporate Communications

Biography unavailable

Mr. Steven Vickers

Vice President of Sales

Biography unavailable

1 / 7